Status:
COMPLETED
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Lead Sponsor:
Synta Pharmaceuticals Corp.
Conditions:
Solid Tumors
Eligibility:
All Genders
25+ years
Phase:
PHASE1
Brief Summary
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Eligibility Criteria
Inclusion
- Patients must be documented to be refractory or not candidates for current approved therapies.
- Must have an ECOG status 0-2.
- Peripheral neuropathy \< or = 2.
- Must have acceptable organ and marrow function per protocol parameters.
- No clinically significant ventricular arrythmias or ischemia.
Exclusion
- Must not be pregnant or breastfeeding.
- Chemotherapy or radiation within 3 weeks.
- Previous radiation to \>25% of total bone marrow.
- Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation.
- Primary brain tumors or active brain metastases.
- Use of any investigational agents within 4 weeks.
- Treatment with chronic immunosuppressants.
- Uncontrolled, intercurrent illness.
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00687934
Start Date
October 1 2007
End Date
October 1 2011
Last Update
September 18 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Premiere Oncology
Santa Monica, California, United States, 90404-2111
2
US Oncology Dayton Oncology and Hematology, P.A
Kettering, Ohio, United States, 45409